The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA moves toward easing restrictions on certain peptides BioPharma Dive BPC 157: Experimental Peptide Creates Risk for Athletes FDA Moves to Reevaluate Several Peptides American Med Spa Association Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives